Highlights Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Real-time Estimate Cboe BZX Other stock markets 12:15:08 2024-05-13 pm EDT			5-day change	1st Jan Change
26.35 ^USD	+1.50%		-0.25%	+190.22%

May. 09	Avidity Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 08	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avidity Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Avidity's Lead Program Gets FDA Breakthrough Designation	May. 08	DJ
Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1	May. 08	CI
Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor? Trial	Mar. 04	CI
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Apprehension About Key Inflation Data Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday	Feb. 29	MT
Avidity Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Avidity Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping	Feb. 20	CI
Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024	Jan. 05	CI
Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44? Trial for Duchenne Muscular Dystrophy	Dec. 13	CI
Avidity Biosciences Collaborates With Bristol Myers to Advance Use of AOC in Multiple Cardiac Targets	Nov. 28	MT
Avidity Biosciences, Inc. Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for Up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology	Nov. 28	CI
Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1	23-10-10	CI
Avidity Biosciences Gets FDA Orphan Drug Label For AOC 1044 in Muscular Dystrophy	23-08-15	MT
Avidity Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Avidity Biosciences, Inc. Provides an Update to the Status of the Partial Clinical Hold Related to Its AOC 1001 Product Candidate	23-05-17	CI
Avidity Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Avidity Biosciences Announces Positive Topline Data from Aoc 1001 Phase 1/2 Marine Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1	23-04-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Highlights

Filters